Intervacc ABFRA:2E9 +48.74%63 Current Ratio is 6.46 as of Mar. 2026, which is 32% above its 10-year median of 4.88. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.06. The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Intervacc AB ranks better than 65.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Intervacc AB's current ratio for the quarter that ended in Mar. 2026 was 6.46.
Intervacc AB has a current ratio of 6.46. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Intervacc AB's Current Ratio or its related term are showing as below:
FRA:2E9'
s Current Ratio Range Over the Past 10 Years
Min: 1.49 Med: 4.88 Max: 12.16
Current: 6.46
During the past 12 years, Intervacc AB's highest Current Ratio was 12.16. The lowest was 1.49. And the median was 4.88.
FRA:2E9's Current Ratio is ranked better than 65.56% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs FRA:2E9: 6.46
Intervacc AB (FRA:2E9) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Intervacc AB Current Ratio Related Terms
Intervacc AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Intervacc AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Intervacc AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (FRA:2E9) has a Current Ratio of 6.46 as of Mar. 2026. This is 32% above median its historical median of 4.88. Over the past decade, Intervacc AB's Current Ratio has ranged from 1.49 to 12.16. According to the industry distribution chart, Intervacc AB ranks #486 out of 1411 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Intervacc AB's Current Ratio too high?
Intervacc AB's current Current Ratio of 6.46 is 32% above median its 10-year median of 4.88. Over the past 10 years, this metric has ranged from a low of 1.49 to a high of 12.16. The Biotechnology industry median Current Ratio is 3.91. Intervacc AB's value of 6.46 is 65.2% above this industry median. Based on the distribution chart, Intervacc AB ranks #486 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #486 out of 1411 companies for Current Ratio. This puts Intervacc AB in the upper half of its industry. The industry median Current Ratio is 3.91. Intervacc AB's value of 6.46 is 65.2% above this benchmark. Historically, Intervacc AB's own Current Ratio has ranged from 1.49 to 12.16 over the past decade. While the company's 10-year median is 4.88 vs. the industry median of 3.91, Intervacc AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intervacc AB's current Current Ratio of 6.46 is 65.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current Current Ratio is 6.46, which is 32% above median its own 10-year median of 4.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Current Ratio of 6.46. The stock's GF Value™ is €0.06, compared to a current price of €0.10 — trading 67.3% above its estimated fair value. The current Current Ratio is 6.46, which is 32% above median its 10-year median of 4.88 and 65.2% above the Biotechnology industry median of 3.91. Intervacc AB's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Current Ratio is 6.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of €0.10 is trading 67.3% above its estimated GF Value™ of €0.06.
Key valuation signals for FRA:2E9:
Current Ratio: 6.46 (32% above median its 10-year median of 4.88)
GF Value™: €0.06 vs. price of €0.10 (67.3% above fair value)
Industry Position: 65.2% above the Biotechnology median (#486 of 1411)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
